IFGL Refractories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2025, 8:46 am

Competitors of IFGL Refractories Ltd

All Competitor Stocks of IFGL Refractories Ltd

Quarterly Result

Last Updated: August 20, 2025, 9:25 am

Below is a detailed analysis of the quarterly data for IFGL Refractories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 454.00 Cr.. The value appears strong and on an upward trend. It has increased from 449.00 Cr. (Mar 2025) to 454.00 Cr., marking an increase of 5.00 Cr..
• For Expenses, as of Jun 2025, the value is 418.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 415.00 Cr. (Mar 2025) to 418.00 Cr., marking an increase of 3.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2025) to 36.00 Cr., marking an increase of 3.00 Cr..
• For OPM %, as of Jun 2025, the value is 8.00%. The value appears strong and on an upward trend. It has increased from 7.00% (Mar 2025) to 8.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 20.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 2.00 Cr..
• For Tax %, as of Jun 2025, the value is 29.00%. The value appears to be improving (decreasing) as expected. It has decreased from 34.00% (Mar 2025) to 29.00%, marking a decrease of 5.00%.
• For Net Profit, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 3.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.50. The value appears strong and on an upward trend. It has increased from 1.17 (Mar 2025) to 1.50, marking an increase of 0.33.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:11 am

Growth

Last Updated: September 5, 2025, 6:50 am

Balance Sheet

Last Updated: June 16, 2025, 11:59 am

Below is a detailed analysis of the balance sheet data for IFGL Refractories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 36.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 36.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,071.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,036.00 Cr. (Mar 2024) to 1,071.00 Cr., marking an increase of 35.00 Cr..
• For Borrowings, as of Mar 2025, the value is 213.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 174.00 Cr. (Mar 2024) to 213.00 Cr., marking an increase of 39.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 298.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 244.00 Cr. (Mar 2024) to 298.00 Cr., marking an increase of 54.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,618.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,490.00 Cr. (Mar 2024) to 1,618.00 Cr., marking an increase of 128.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 593.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2024) to 593.00 Cr., marking an increase of 76.00 Cr..
• For CWIP, as of Mar 2025, the value is 27.00 Cr.. The value appears to be declining and may need further review. It has decreased from 104.00 Cr. (Mar 2024) to 27.00 Cr., marking a decrease of 77.00 Cr..
• For Investments, as of Mar 2025, the value is 105.00 Cr.. The value appears to be declining and may need further review. It has decreased from 126.00 Cr. (Mar 2024) to 105.00 Cr., marking a decrease of 21.00 Cr..
• For Other Assets, as of Mar 2025, the value is 893.00 Cr.. The value appears strong and on an upward trend. It has increased from 743.00 Cr. (Mar 2024) to 893.00 Cr., marking an increase of 150.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,618.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,490.00 Cr. (Mar 2024) to 1,618.00 Cr., marking an increase of 128.00 Cr..

Notably, the Reserves (1,071.00 Cr.) exceed the Borrowings (213.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for IFGL Refractories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 11.93. This value is within the healthy range. It has decreased from 22.66 (Mar 24) to 11.93, marking a decrease of 10.73.
• For Diluted EPS (Rs.), as of Mar 25, the value is 11.93. This value is within the healthy range. It has decreased from 22.66 (Mar 24) to 11.93, marking a decrease of 10.73.
• For Cash EPS (Rs.), as of Mar 25, the value is 32.11. This value is within the healthy range. It has decreased from 40.50 (Mar 24) to 32.11, marking a decrease of 8.39.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 307.17. It has increased from 297.47 (Mar 24) to 307.17, marking an increase of 9.70.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 307.17. It has increased from 297.47 (Mar 24) to 307.17, marking an increase of 9.70.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 458.67. It has increased from 454.92 (Mar 24) to 458.67, marking an increase of 3.75.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 40.52. This value is within the healthy range. It has decreased from 48.04 (Mar 24) to 40.52, marking a decrease of 7.52.
• For PBIT / Share (Rs.), as of Mar 25, the value is 20.34. This value is within the healthy range. It has decreased from 30.21 (Mar 24) to 20.34, marking a decrease of 9.87.
• For PBT / Share (Rs.), as of Mar 25, the value is 16.52. This value is within the healthy range. It has decreased from 27.15 (Mar 24) to 16.52, marking a decrease of 10.63.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 11.93. This value is within the healthy range. It has decreased from 22.66 (Mar 24) to 11.93, marking a decrease of 10.73.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.93. This value is within the healthy range. It has decreased from 22.66 (Mar 24) to 11.93, marking a decrease of 10.73.
• For PBDIT Margin (%), as of Mar 25, the value is 8.83. This value is below the healthy minimum of 10. It has decreased from 10.56 (Mar 24) to 8.83, marking a decrease of 1.73.
• For PBIT Margin (%), as of Mar 25, the value is 4.43. This value is below the healthy minimum of 10. It has decreased from 6.64 (Mar 24) to 4.43, marking a decrease of 2.21.
• For PBT Margin (%), as of Mar 25, the value is 3.60. This value is below the healthy minimum of 10. It has decreased from 5.96 (Mar 24) to 3.60, marking a decrease of 2.36.
• For Net Profit Margin (%), as of Mar 25, the value is 2.59. This value is below the healthy minimum of 5. It has decreased from 4.98 (Mar 24) to 2.59, marking a decrease of 2.39.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.59. This value is below the healthy minimum of 8. It has decreased from 4.98 (Mar 24) to 2.59, marking a decrease of 2.39.
• For Return on Networth / Equity (%), as of Mar 25, the value is 3.88. This value is below the healthy minimum of 15. It has decreased from 7.61 (Mar 24) to 3.88, marking a decrease of 3.73.
• For Return on Capital Employeed (%), as of Mar 25, the value is 6.09. This value is below the healthy minimum of 10. It has decreased from 9.24 (Mar 24) to 6.09, marking a decrease of 3.15.
• For Return On Assets (%), as of Mar 25, the value is 2.65. This value is below the healthy minimum of 5. It has decreased from 5.48 (Mar 24) to 2.65, marking a decrease of 2.83.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has increased from 0.15 (Mar 24) to 0.18, marking an increase of 0.03.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.06. It has decreased from 1.12 (Mar 24) to 1.06, marking a decrease of 0.06.
• For Current Ratio (X), as of Mar 25, the value is 2.28. This value is within the healthy range. It has decreased from 2.68 (Mar 24) to 2.28, marking a decrease of 0.40.
• For Quick Ratio (X), as of Mar 25, the value is 1.31. This value is within the healthy range. It has decreased from 1.72 (Mar 24) to 1.31, marking a decrease of 0.41.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.69. This value is within the healthy range. It has increased from 2.46 (Mar 24) to 4.69, marking an increase of 2.23.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 58.69. This value exceeds the healthy maximum of 50. It has increased from 30.88 (Mar 24) to 58.69, marking an increase of 27.81.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 21.80. This value is within the healthy range. It has increased from 17.28 (Mar 24) to 21.80, marking an increase of 4.52.
• For Earning Retention Ratio (%), as of Mar 25, the value is 41.31. This value is within the healthy range. It has decreased from 69.12 (Mar 24) to 41.31, marking a decrease of 27.81.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 78.20. This value exceeds the healthy maximum of 70. It has decreased from 82.72 (Mar 24) to 78.20, marking a decrease of 4.52.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 10.62. This value is within the healthy range. It has decreased from 15.69 (Mar 24) to 10.62, marking a decrease of 5.07.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.13. This value is within the healthy range. It has decreased from 8.40 (Mar 24) to 4.13, marking a decrease of 4.27.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,401.63. It has decreased from 2,039.82 (Mar 24) to 1,401.63, marking a decrease of 638.19.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.24 (Mar 24) to 0.84, marking a decrease of 0.40.
• For EV / EBITDA (X), as of Mar 25, the value is 9.60. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 9.60, marking a decrease of 2.18.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 1.19 (Mar 24) to 0.76, marking a decrease of 0.43.
• For Retention Ratios (%), as of Mar 25, the value is 41.30. This value is within the healthy range. It has decreased from 69.11 (Mar 24) to 41.30, marking a decrease of 27.81.
• For Price / BV (X), as of Mar 25, the value is 1.14. This value is within the healthy range. It has decreased from 1.82 (Mar 24) to 1.14, marking a decrease of 0.68.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 1.19 (Mar 24) to 0.76, marking a decrease of 0.43.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness